4.6 Article

Role of Cardiac CT in Pre-Procedure Planning for Transcatheter Mitral Valve Replacement

期刊

JACC-CARDIOVASCULAR IMAGING
卷 14, 期 8, 页码 1571-1580

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jcmg.2020.12.018

关键词

cardiac CT; LVOT obstruction; TMVR

资金

  1. Heart & Stroke Foundation/University of Toronto Polo Chair in Cardiology Young Investigator Award
  2. Abbott
  3. Edwards
  4. Daiichi Sankyo
  5. Boehringer Ingelheim
  6. CSL Behring
  7. Ferring Pharmaceuticals
  8. Bayer
  9. Afimmune
  10. Amarin
  11. Amgen
  12. AstraZeneca
  13. Bristol-Myers Squibb
  14. Cardax
  15. Chiesi
  16. Eisai
  17. Ethicon
  18. Forest Laboratories
  19. Fractyl
  20. Idorsia
  21. Ironwood
  22. Ischemix
  23. Lexicon
  24. Lilly
  25. Medtronic
  26. Pfizer
  27. PhaseBio
  28. PLx Pharma
  29. Regeneron
  30. Roche
  31. Sanofi Aventis
  32. Synaptic
  33. Medicines Company

向作者/读者索取更多资源

The study found that only a minority of patients referred for TMVR planning actually underwent the procedure, with CCT technology being able to identify unsuitable anatomy and leading to exclusion in a significant number of cases.
OBJECTIVES This study sought to evaluate cardiac computed tomography (CCT) findings and their clinical impact among patients being considered for transcatheter mitral valve replacement (TMVR). BACKGROUND CCT is used to evaluate whether patients are candidates for TMVR, but limited data exist on the yield of such tests. METHODS Patients referred for pre-procedural CCT for TMVR planning in the context of failing mitral bioprosthetic valves, annuloplasty rings, and severe native valve disease with annular calcification were included in this study. CCT findings were analyzed to evaluate for suitability for TMVR. In the subset of patients who underwent TMVR, echocardiographic and procedural characteristics were recorded. RESULTS Among 80 patients who underwent pre-procedural CCT, the mean age was 71.8 +/- 11.4 years, 60% were women, and the mean Society of Thoracic Surgeon score was 9.4 +/- 6.7. Most cases were referred for valve-in-native annular calcifi-cation planning (n = 43), followed by valve-in-valve (n = 29), and valve-in-ring procedures (n = 8). A total of 51 (64%) patients did not undergo TMVR, 37 of whom had high-risk features identified on CCT. The most common reason for exclusion was related to large annular size, followed by heightened risk of left ventricular outflow tract (LVOT) obstruction. Among 29 patients (36%) who underwent TMVR, the 30-day mortality rate was 17%. Five patients experienced LVOT obstruction, 4 of whom were predicted by CCT. Following TMVR, 5 patients had at least moderate peri-valvular regurgitation. CONCLUSIONS A minority of patients referred for TMVR planning ultimately undergo the procedure. CCT identifies unsuitable anatomy and leads to exclusion in a significant number of cases.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据